| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Experimental Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents. The efficacy of 4HPR alone and in combination with cisplatin was tested against the human ovarian carcinoma IGROV-1 xenograft i.p. Administration p.o. of 4HPR was not effective, whereas intracavitary treatment significantly increased the survival time of treated mice. It also enhanced the antitumor activity of cisplatin. These findings suggest that 4HPR may be an active agent against epithelial ovarian tumors.
1 This work was supported in part by the Istituto Superiore della Sanità (Italy-USA Program on New Therapies of Neoplasia), by Associazione Italiana per la Ricerca sul Cancro and by Ministero della Sanità.
2 To whom requests for reprints should be addressed, at the Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
Received 8/ 9/93. Accepted 10/ 5/93.
This article has been cited by other articles:
![]() |
P. E. Lovat, M. Corazzari, J. L. Armstrong, S. Martin, V. Pagliarini, D. Hill, A. M. Brown, M. Piacentini, M. A. Birch-Machin, and C. P.F. Redfern Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress Cancer Res., July 1, 2008; 68(13): 5363 - 5369. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Sabichi, S. P. Lerner, E. N. Atkinson, H. B. Grossman, N. P. Caraway, C. P. Dinney, D. F. Penson, S. Matin, A. Kamat, L. L. Pisters, et al. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer Clin. Cancer Res., January 1, 2008; 14(1): 224 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.-C. Sun, R. T. McKee, et al. Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex Clin. Cancer Res., May 15, 2007; 13(10): 3079 - 3086. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Colombo, F. Formelli, M. G. Cantu, G. Parma, M. Gasco, A. Argusti, A. Santinelli, R. Montironi, E. Cavadini, L. Baglietto, et al. A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1914 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Myatt, C. P.F. Redfern, and S. A. Burchill p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death Clin. Cancer Res., April 15, 2005; 11(8): 3136 - 3148. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Moreb, A. Gabr, G. R. Vartikar, S. Gowda, J. R. Zucali, and D. Mohuczy Retinoic Acid Down-Regulates Aldehyde Dehydrogenase and Increases Cytotoxicity of 4-Hydroperoxycyclophosphamide and Acetaldehyde J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 339 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Prasad Multiple Dietary Antioxidants Enhance the Efficacy of Standard and Experimental Cancer Therapies and Decrease Their Toxicity Integr Cancer Ther, December 1, 2004; 3(4): 310 - 322. [Abstract] [PDF] |
||||
![]() |
C. M. Finnegan, S. S. Rawat, A. Puri, J. M. Wang, F. W. Ruscetti, and R. Blumenthal Ceramide, a target for antiretroviral therapy PNAS, October 26, 2004; 101(43): 15452 - 15457. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Villani, V. Appierto, E. Cavadini, M. Valsecchi, S. Sonnino, R. W. Curley, and F. Formelli Identification of the Fenretinide Metabolite 4-Oxo-Fenretinide Present in Human Plasma and Formed in Human Ovarian Carcinoma Cells through Induction of Cytochrome P450 26A1 Clin. Cancer Res., September 15, 2004; 10(18): 6265 - 6275. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Donald, R. D. Verschoyle, P. Greaves, T. W. Gant, T. Colombo, M. Zaffaroni, R. Frapolli, M. Zucchetti, M. D'Incalci, D. Meco, et al. Complete Protection by High-Dose Dexamethasone against the Hepatotoxicity of the Novel Antitumor Drug Yondelis (ET-743) in the Rat Cancer Res., September 15, 2003; 63(18): 5902 - 5908. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF] |
||||
![]() |
D. Cvetkovic, S. J. Williams, and T. C. Hamilton Loss of Cellular Retinol-binding Protein 1 Gene Expression in Microdissected Human Ovarian Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1013 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Brewer, K. Johnson, M. Follen, D. Gershenson, and R. Bast Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res., January 1, 2003; 9(1): 20 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bruno, C. Tenca, D. Saverino, E. Ciccone, and C. E. Grossi Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment Carcinogenesis, March 1, 2002; 23(3): 447 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Prasad, W. C. Cole, B. Kumar, and K. C. Prasad Scientific Rationale for Using High-Dose Multiple Micronutrients as an Adjunct to Standard and Experimental Cancer Therapies J. Am. Coll. Nutr., October 1, 2001; 20(90005): 450S - 463. [Abstract] [Full Text] |
||||
![]() |
S.-Y. Sun, P. Yue, G. J. Kelloff, V. E. Steele, S. M. Lippman, W. K. Hong, and R. Lotan Identification of Retinamides That Are More Potent than N-(4-Hydroxyphenyl)retinamide in Inhibiting Growth and Inducing Apoptosis of Human Head and Neck and Lung Cancer Cells Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 595 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Veronesi and A. Decensi Retinoids for Ovarian Cancer Prevention: Laboratory Data Set the Stage for Thoughtful Clinical Trials J Natl Cancer Inst, April 4, 2001; 93(7): 486 - 488. [Full Text] [PDF] |
||||
![]() |
B. J. Maurer, L. Melton, C. Billups, M. C. Cabot, and C. P. Reynolds Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism J Natl Cancer Inst, December 6, 2000; 92(23): 1897 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, and C. P. Reynolds Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)- retinamide in Neuroblastoma Cell Lines J Natl Cancer Inst, July 7, 1999; 91(13): 1138 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Sun, W. Li, P. Yue, S. M. Lippman, W. K. Hong, and R. Lotan Mediation of N-(4-Hydoxyphenyl)retinamide-induced Apoptosis in Human Cancer Cells by Different Mechanisms Cancer Res., May 1, 1999; 59(10): 2493 - 2498. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Sun, P. Yue, and R. Lotan Induction of Apoptosis by N-(4-Hydroxyphenyl)retinamide and Its Association with Reactive Oxygen Species, Nuclear Retinoic Acid Receptors, and Apoptosis-Related Genes in Human Prostate Carcinoma Cells Mol. Pharmacol., March 1, 1999; 55(3): 403 - 410. [Abstract] [Full Text] |
||||
![]() |
H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide Carcinogenesis, February 1, 1999; 20(2): 229 - 236. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |